Literature DB >> 12544092

Gene expression profiling of melanocytic lesions.

John T Seykora1, Debbie Jih, Rosalie Elenitsas, Wen-Hwai Horng, David E Elder.   

Abstract

DNA microarrays, microscopic grids of DNA, can be used to assess gene expression within a particular cell or cell population. Since DNA from thousands of genes can be hybridized and analyzed in one experiment, researchers can globally characterize genes expressed in normal and various pathologic states. To accurately assess the differences between normal and pathologic states, one derives cDNA from control and diseased tissue specimens for genes expression profiling. For these reasons, microarray technology may be of particular interest to dermatopathologists and dermatologists interested in understanding cutaneous disease because these physicians have access to tissue specimens. In addition, microarray technology is an efficient way of identifying molecules expressed in a cell population; therefore, it can be used to search for unique immunohistologic markers. To this end, we have used microarray technology to define differences in the gene expression profile of nevi and melanomas. In this manuscript, we discuss the results of our study, which confirm previously known differences in gene expression between melanoma and nevi. While a few genes appear slightly overexpressed in nevi, a number of genes involved in regulating cell proliferation were upregulated in melanoma, such as cyclin D1, cdc2-related protein kinase, c-Myc binding protein, early growth response protein 1, and pleiotrophin. "Housekeeping" genes such as glyceraldehyde 3-phosphate dehydrogenase were expressed at similar levels in melanoma and nevi. Surprisingly, a majority of genes were expressed at similar levels in both nevi and melanoma. Based on this study, DNA microarray technology appears to be a valuable tool for identifying genes that may be specifically expressed in cutaneous lesions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12544092     DOI: 10.1097/00000372-200302000-00002

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  7 in total

1.  Pleiotrophin regulates lung epithelial cell proliferation and differentiation during fetal lung development via beta-catenin and Dlk1.

Authors:  Tingting Weng; Li Gao; Manoj Bhaskaran; Yujie Guo; Deming Gou; Jeyaparthasarathy Narayanaperumal; Narendranath Reddy Chintagari; Kexiong Zhang; Lin Liu
Journal:  J Biol Chem       Date:  2009-08-06       Impact factor: 5.157

Review 2.  The role of pleiotrophin and beta-catenin in fetal lung development.

Authors:  Tingting Weng; Lin Liu
Journal:  Respir Res       Date:  2010-06-18

3.  Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression.

Authors:  William K Kaufmann; Kathleen R Nevis; Pingping Qu; Joseph G Ibrahim; Tong Zhou; Yingchun Zhou; Dennis A Simpson; Jennifer Helms-Deaton; Marila Cordeiro-Stone; Dominic T Moore; Nancy E Thomas; Honglin Hao; Zhi Liu; Janiel M Shields; Glynis A Scott; Norman E Sharpless
Journal:  J Invest Dermatol       Date:  2007-06-28       Impact factor: 8.551

Review 4.  Genetic pathways to melanoma tumorigenesis.

Authors:  M R Hussein
Journal:  J Clin Pathol       Date:  2004-08       Impact factor: 3.411

5.  Menin represses malignant phenotypes of melanoma through regulating multiple pathways.

Authors:  Shu-Bin Gao; Zi-Jie Feng; Bin Xu; Yan Chen; Hong-Hua Zheng; Ping Yin; Xianxin Hua; Guang-Hui Jin
Journal:  J Cell Mol Med       Date:  2011-11       Impact factor: 5.310

6.  Molecular markers of tumor progression in melanoma.

Authors:  Joshua Rother; Dan Jones
Journal:  Curr Genomics       Date:  2009-06       Impact factor: 2.236

7.  Global analysis of gene expression changes during retinoic acid-induced growth arrest and differentiation of melanoma: comparison to differentially expressed genes in melanocytes vs melanoma.

Authors:  Mary Estler; Goran Boskovic; James Denvir; Sarah Miles; Donald A Primerano; Richard M Niles
Journal:  BMC Genomics       Date:  2008-10-11       Impact factor: 3.969

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.